Nextwave Drug Patent Portfolio
Nextwave owns 1 orange book drug protected by 7 US patents Given below is the list of Nextwave's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
| US8465765 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
| US8563033 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
| US8778390 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
| US8956649 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
| US9040083 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
| US8062667 | Modified release formulations containing drug-ion exchange resin complexes | 29 Mar, 2029 | Active |
Latest Legal Activities on Nextwave's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nextwave.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Apr, 2024 | US8287903 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Nov, 2022 | US9040083 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Dec, 2021 | US8778390 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Apr, 2021 | US8563033 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Oct, 2020 | US8465765 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Apr, 2020 | US8287903 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Nov, 2018 | US9040083 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Jan, 2018 | US8778390 (Litigated) |
|
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US8778390 (Litigated) |
|
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US8563033 (Litigated) |
|
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US9040083 |
|
Recordation of Patent Grant Mailed
Critical
| 26 May, 2015 | US9040083 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 26 May, 2015 | US9040083 |
|
Email Notification
Critical
| 07 May, 2015 | US9040083 |
|
Issue Notification Mailed
Critical
| 06 May, 2015 | US9040083 |
Nextwave's Family Patents
Nextwave drugs have patent protection in a total of 14 countries. It has a significant patent presence in the US with 58.3% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Nextwave Drug List
Given below is the complete list of Nextwave's drugs and the patents protecting them.
1. Quillivant Xr
Quillivant Xr is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(5 years from now)
| Active |
| US8465765 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(5 years from now)
| Active |
| US8563033 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(5 years from now)
| Active |
| US8778390 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(5 years from now)
| Active |
| US8956649 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(5 years from now)
| Active |
| US9040083 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(5 years from now)
| Active |
| US8062667 | Modified release formulations containing drug-ion exchange resin complexes |
29 Mar, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Quillivant Xr's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List